Edition:
United States

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

15.06USD
15 Jun 2018
Change (% chg)

$-0.48 (-3.09%)
Prev Close
$15.54
Open
$15.50
Day's High
$15.51
Day's Low
$15.04
Volume
2,811
Avg. Vol
8,560
52-wk High
$51.90
52-wk Low
$15.04

Chart for

About

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was... (more)

Overall

Beta: -0.52
Market Cap(Mil.): $40.62
Shares Outstanding(Mil.): 2.70
Dividend: --
Yield (%): --

Financials

  OPNT.OQ Industry Sector
P/E (TTM): -- 29.97 34.18
EPS (TTM): -6.00 -- --
ROI: -112.46 13.65 13.17
ROE: -162.56 15.43 15.15

BRIEF-Opiant Pharma Reports Financial Results

* OPIANT PHARMACEUTICALS, INC. REPORTS FINANCIAL RESULTS FOR AUGUST 1, 2017, THROUGH DECEMBER 31, 2017, AND PROVIDES CORPORATE UPDATE Source text for Eikon: Further company coverage:

Mar 07 2018

BRIEF-Opiant Pharma Says Teva Filed ANDA With FDA For Marketing Approval Of Generic Version Of Narcan 2 Mg/Spray

* OPIANT PHARMACEUTICALS SAYS ON FEB 27, CO AND ADAPT PHARMA OPERATIONS LIMITED RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA INC - SEC FILING

Mar 05 2018

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003

Feb 12 2018

BRIEF-Opiant Pharmaceuticals To Record About $11.7 Million In Royalty

* OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

Feb 08 2018

BRIEF-Opiant Pharmaceuticals Receives About $5.3 Mln Of Cash From Exercise Of Outstanding Warrants

* OPIANT PHARMACEUTICALS RECEIVES APPROXIMATELY $5.3 MILLION OF CASH FROM EXERCISE OF OUTSTANDING WARRANTS Source text for Eikon: Further company coverage:

Jan 02 2018

BRIEF-Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose

* OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

Dec 20 2017

Earnings vs. Estimates